Inhibrx, Inc.
inhibrx.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q1 FY2024 10-Q, filed May 9, 2024. Its latest SEC filing is a SC 13G/A from Nov 14, 2024.
10-Q for Q1 FY2024, filed May 9, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops biologic drug candidates for people with cancer and alpha one antitrypsin deficiency using protein-engineering platforms.
10-K for FY2023, filed Feb 28, 2024We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary…View ↗
INBRX-101, which seeks to maintain the natural function of Alpha-1 antitrypsin, or AAT, in a recombinant format, optimized for less…View ↗
Our most advanced therapeutic candidate, INBRX-109, is a tetravalent death receptor 5, or DR5, agonist currently being evaluated in…View ↗
How Did They Make Money?
It receives fees and research funding from collaboration partners, milestone payments, and royalties tied to product sales; it also receives grants. License and milestone payments are tied to a license transfer or milestone achievement, research funding to work performed over time, and royalties to product sales.
10-K for FY2023, filed Feb 28, 2024The Company has generated revenue from its license and collaboration agreements with partners, as well as from grants from government…View ↗
The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the…View ↗
Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments…View ↗
The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether…View ↗
$1.8M
-
10-K for FY2023, filed Feb 28, 2024
$1.8M ↗
Who Were Their Customers?
Collaboration partners enter license and research agreements; government agencies and private nonprofit organizations provide grants.
10-K for FY2023, filed Feb 28, 2024
Did Revenues Turn Into Profits?
No. It lost $241.4M in FY2023.
10-K for FY2023, filed Feb 28, 2024
−$219.2MView ↗
10-K for FY2023, filed Feb 28, 2024
−$241.4MView ↗
10-K for FY2023, filed Feb 28, 2024
−$197.9MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q1 FY2024, filed May 10, 2024
−$78.7MView ↗
- ▲ +61% (Loss)
- vs −$48.9M in Q1 FY2023
-
May 30, 2024
Inhibrx completed its merger and became a wholly owned subsidiary
Shareholders became entitled to cash and contingent value rights; the company requested suspension of trading and delisting.
Sources
8-K, filed May 30, 2024
At the Effective Time, each share of Company common stock that was issued and outstanding immediately prior to the Effective Time (other…View ↗
Shrank. Revenue fell 86% in 4 years, from $13.2M in FY2019 to $1.8M in FY2023, about 39% a year.
A cancer program was discontinued
A cancer candidate that the older report described as in clinical trials was later terminated, and the company planned to wind down its trial.
10-K for FY2020, filed Mar 12, 2021 10-K for FY2023, filed Feb 28, 2024We currently have four programs in ongoing clinical trials, with the most advanced expected to initiate a registration-enabling trial in…View ↗
We have decided to terminate our INBRX-105 program, a tetravalent programmed death-ligand 1, or PD-L1, targeted 4-1BB agonist. During the…View ↗
Who Did They Compete With?
Competes with Alligator Bioscience, Crescendo Biologics, GlaxoSmithKline, IGM Biosciences, Lava Therapeutics, Molecular Partners, Pieris Pharmaceuticals, Precirix, Sanofi, Regeneron Pharmaceuticals, Adimab, Genmab, Macrogenics, Merus, MorphoSys, Numab Therapeutics, Amgen, Xencor, Zymeworks, and CSL
10-K for FY2023, filed Feb 28, 2024Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Alligator Bioscience AB…View ↗
Loading...
